The intravenous administration of monocytic myeloid-derived suppressor cells, or M-MDSCs, proved promising in treating rheumatoid arthritis in mice, inhibiting T cell proliferation, as well as B cell proliferation and antibody production. "I hope this study will lead to a better understanding of MDSCs' potential in cell-based therapies against autoimmune diseases," said Dr. Peng Liu, a researcher involved in the work from the Department of Medicine at the University of North Carolina at Chapel Hill. Release